Amgen, a biotechnology firm, agreed to acquire Rodeo Therapeutics, a developer of small-molecule therapies, from Accelerator Life Science Partners, a venture capital firm, for c.$720m. "With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and conditions, Amgen is ideally positioned to rapidly advance our program into the clinic," Thong Q. Le, Rodeo President and CEO.